Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ear tubes & middle ear surgery cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (93 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 326 | 33% |
| 2020 | 0 | 175 | 36% |
| 2021 | 0 | 176 | 39% |
| 2022 | 1 | 194 | 41% |
| 2023 | 4 | 303 | 43% |
| 2024 | 2 | 258 | 45% |
| 2025 from claims | – | 192 155–225 | 46% |
| 2026 forecast | – | 194 152–244 | 46% |
| 2027 forecast | – | 197 146–260 | 47% |
| 2028 forecast | – | 200 141–275 | 47% |
| 2029 forecast | – | 202 137–290 | 47% |
| 2030 forecast | – | 205 134–304 | 48% |
Tympanostomy tubes, tympanoplasty, and ossicular reconstruction: mostly children and working-age adults. Professional codes (what the surgeon bills): CPT 69436, 69631, 69633, 69641.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Jersey; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% surgery center. The share outside the hospital has moved +25 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 8 | 528−9.9%/yr | −9.9%/yr | 0.4 | 47% | 490 in 2030−1.1%/yr |
| New York | 2 | 294−9%/yr | −9%/yr | 0.2 | 17% | 260 in 2030−2.2%/yr |
| Massachusetts | 0 | 237−3.1%/yr | −3.1%/yr | 0.3 | 36% | 130 in 2030−10%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 22 | 3,263+0.4%/yr | +0.4%/yr | 3.10.9× | 94% | 4,190 in 2030+4.2%/yr |
Ear tubes & middle ear surgery in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with Pennsylvania
Smith+Nephew leads with 93% of company spending on these surgeons in 2025, −1 pts on 2024.
In 2025, 2 companies reported engagement with New Jersey’s surgeons worth $11K in consulting, speaking, meals and travel tied to these products, about $5,510 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.